Recent clinical data suggests that Novera Retatrutide, a twin-action medication from Novo Nordisk, could represent a significant breakthrough in body management. Beyond many existing drugs, Retatrutide targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (… Read More